BTIG Maintains Buy on DexCom, Raises Price Target to $96

BTIG analyst Ryan Zimmerman has maintained a 'Buy' rating on DexCom (NASDAQ: DXCM) and increased the price target from $90 to $96. This adjustment reflects a positive outlook on the company's performance.